Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04350138 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection
A Phase 2 study of Gonococcal Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Active
- Registry status
- Phase 2
- Development phase
- 2,606
- Enrollment target
- 13
- Study locations
NCT04350138 is a Phase 2 study of Gonococcal Infection that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,606 participants. The trial reports 13 study locations across 10 states.
The verdict
NCT04350138, a Phase 2 study of Gonococcal Infection, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 2,606 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection. Approximately 2,200 participants are expected to be enrolled to achieve at least 202 primary endpoints in the Per Protocol Population. Data will be collected in an observer-blind manner. Study product recipients and study staff responsible for the evaluation of any study endpoint will be unaware of whether Bexsero or placebo were administered. The duration of the study for participants who are enrolled and randomized will be approximately 16 months. Study participation is expected to be completed in approximately 36 months. The primary objective of the study is to demonstrate efficacy of Bexsero in prevention of urogenital and/or anorectal gonococcal infection.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Meningococcal Group B Vaccine
Study Locations (13)
California
- UCLA Clinical AIDS Research and Education (CARE) Center - Los Angeles
- SFDPH Bridge HIV Center - San Francisco
Georgia
- Emory University School of Medicine - The Ponce de Leon Center - Atlanta
- Emory University Hospital Midtown - Emory Clinic Infectious Diseases - Atlanta
Other
- The Thai Red Cross AIDS Research Centre - Bangkok
- Armed Forces Research Institute of Medical Sciences - Royal Thai Army Clinical Research Center - Bangkok
Alabama
- University of Alabama at Birmingham School of Medicine - Infectious Disease - Birmingham
Illinois
- University of Illinois at Chicago College of Medicine - Division of Infectious Diseases - Chicago
Louisiana
- LSU - CrescentCare Sexual Health Center - New Orleans
Maryland
- Walter Reed National Military Medical Center - Bethesda
New York
- Harlem Prevention Center, Columbia University, Mailman School of Public Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,606 participants |
| Start Date | 2020-12-29 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04350138
The ClinicalTrials.gov registry entry for NCT04350138 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 2,606 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gonococcal Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04350138 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, Georgia, Other.
Frequently Asked Questions
What is clinical trial NCT04350138 about?
NCT04350138 is a clinical study titled "Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection". This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection. Approximately 2,200 participant...
What is the current status of trial NCT04350138?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 2,606 participants. The study started on 2020-12-29. Estimated completion is 2026-10-01.
What conditions does trial NCT04350138 study?
This clinical trial studies the following conditions: Gonococcal Infection.
What interventions are being tested in trial NCT04350138?
The interventions under investigation include: Placebo (OTHER), Meningococcal Group B Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04350138?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04350138 being conducted?
This trial has 13 study locations across Alabama, California, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gonococcal Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.